JP2016515620A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515620A5
JP2016515620A5 JP2016506353A JP2016506353A JP2016515620A5 JP 2016515620 A5 JP2016515620 A5 JP 2016515620A5 JP 2016506353 A JP2016506353 A JP 2016506353A JP 2016506353 A JP2016506353 A JP 2016506353A JP 2016515620 A5 JP2016515620 A5 JP 2016515620A5
Authority
JP
Japan
Prior art keywords
xaa
group
lys
ala
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016506353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515620A (ja
Filing date
Publication date
Priority claimed from US14/229,799 external-priority patent/US20140294902A1/en
Application filed filed Critical
Publication of JP2016515620A publication Critical patent/JP2016515620A/ja
Publication of JP2016515620A5 publication Critical patent/JP2016515620A5/ja
Pending legal-status Critical Current

Links

JP2016506353A 2013-04-02 2014-03-31 新規のα4β7ペプチド拮抗薬 Pending JP2016515620A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361807713P 2013-04-02 2013-04-02
US61/807,713 2013-04-02
US14/229,799 2014-03-28
US14/229,799 US20140294902A1 (en) 2013-04-02 2014-03-28 Novel a4b7 peptide antagonists
PCT/US2014/032392 WO2014165449A1 (en) 2013-04-02 2014-03-31 NOVEL α4β7 PEPTIDE ANTAGONISTS

Publications (2)

Publication Number Publication Date
JP2016515620A JP2016515620A (ja) 2016-05-30
JP2016515620A5 true JP2016515620A5 (enExample) 2017-05-18

Family

ID=51621090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506353A Pending JP2016515620A (ja) 2013-04-02 2014-03-31 新規のα4β7ペプチド拮抗薬

Country Status (4)

Country Link
US (2) US20140294902A1 (enExample)
EP (1) EP2981543A4 (enExample)
JP (1) JP2016515620A (enExample)
WO (1) WO2014165449A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
CN106366160B (zh) * 2016-10-11 2019-06-14 厦门大学 基于二硫键精准配对构建富含二硫键多肽分子骨架的方法
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2019285831B2 (en) * 2018-06-13 2023-11-16 Revolo Biotherapeutics Limited Novel protein with anti-inflammatory properties
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
US20230145835A1 (en) * 2021-10-06 2023-05-11 48Hd Biopharma Inc. Modulators of Alpha-4-beta-7 Integrin and MAdCAM
CN116098884B (zh) * 2022-12-12 2024-04-19 山东大学 一种n-乙酰-l-酪氨酸在制备治疗炎症性肠病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0578728T3 (da) * 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
GB9613112D0 (en) * 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
EP0998309A1 (en) * 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Methods and systems for preparing and sealing radiation delivery structures
EP1100473A2 (en) * 1998-07-28 2001-05-23 InnerDyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
WO2001068586A2 (en) * 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (de) * 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2109480B1 (en) * 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
JP2011231085A (ja) * 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis

Similar Documents

Publication Publication Date Title
JP2016515620A5 (enExample)
JP2016518351A5 (enExample)
JP2015533833A5 (enExample)
JP2017522362A5 (enExample)
JP2017535527A5 (enExample)
RU2017114414A (ru) НОВЫЕ АНТАГОНИСТЫ α4β7 НА ОСНОВЕ МОНОМЕРНЫХ И ДИМЕРНЫХ ПЕПТИДОВ
AU2014228460B2 (en) Pharmaceutical compositions
JP2016515620A (ja) 新規のα4β7ペプチド拮抗薬
JP2012067099A5 (enExample)
JP2025163134A (ja) コンジュゲートされたヘプシジン模倣物
KR20160068951A (ko) 글루카곤 유사체
US8748575B2 (en) Therapeutic peptides
CA2733006A1 (en) Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
WO2011079015A1 (en) Rgd-containing cyclic peptides
KR20250043599A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
WO2018128828A1 (en) Novel hepcidin mimetics and uses thereof
CA2769883A1 (en) Use of melanocortins to treat dyslipidemia
CN102482323A (zh) 新型肽及其应用
LV10108B (en) Inhibitors of cells proliferation, pharmaceutical composition, process of producing of compounds, methods of inhibition of cellular proliferation
JP2020055873A (ja) 白血球動員をブロックするペプチドおよび使用方法
EP3096795B1 (en) Activated neurotensin molecules and the uses thereof
CA2405704C (en) Bombesin analogs for treatment of cancer
US20150174207A1 (en) Methods for treating cancer with ghrh agonists
CN101531707A (zh) 新型抗肿瘤化合物
WO2022188628A1 (zh) 一类阿片/神经肽ff受体多靶点环肽分子及其制备和应用